We use cookies on our website to provide you with the best possible service and to further improve our website. By clicking the "Accept All" button, you agree to the use of all cookies. You can limit the cookies used by clicking on "Accept selection". Further information and an option to revoke your selection can be found in our privacy policy.
These cookies are necessary for basic functionality. This allows you to register on our website and forum or order products with our online shop.
With these cookies, we collect anonymized usage data for our website. For example, we can see which content is interesting for our visitors and which resolutions are used. We use the information to optimize our website to provide you with the best possible user experience.
show more
CheckMate 9X8 is a randomized phase II/III trial investigating the efficacy of combining Immune Checkpoint Inhibitors (ICIs) with standard chemotherapy in patients with Metastatic Colorectal Cancer (mCRC). 2.
CheckMate 9X8 is part of a broader field of study, alongside trials like AtezoTRIBE and MEDITREME, testing similar immunotherapeutic approaches. 4. Preliminary Findings & Objectives Destro 9x8
Based on the available search results, the "Destro 9x8" appears to refer to the , an ongoing clinical study in metastatic colorectal cancer (mCRC), often discussed in literature regarding immuno-oncology. Report: CheckMate 9X8 Trial Overview 1. Subject CheckMate 9X8 is a randomized phase II/III trial
T-cell activation through "immunogenic cell death" to overcome traditional resistance to immunotherapy in MSS (microsatellite stable) colorectal cancer. 3. alongside trials like AtezoTRIBE and MEDITREME
While immunotherapy has revolutionized cancer treatment, many colorectal cancers (specifically MSS/pMMR) have historically responded poorly to single-agent immunotherapy.
Combining chemotherapy with ICIs like nivolumab aims to convert "cold" tumors (non-responsive) into "hot" tumors (immune-active).
Deutsch
English
Français
Chinese 中文
Korean